This inventor holds 4 USPTO granted patents. Top assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited, University of Michigan. Active years: 2013-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ann Arbor, MI (US) (2013)
- Jiangsu, CN (2022)
- Suzhou, CN (2022 - 2023)
Company Filing History:
3 out of 31 
3 out of 29 
3 out of 3,546 
Years Active: 2013-2023
Title: Discovering the Innovations of Guozhi Tang
Introduction
Guozhi Tang is a prominent inventor based in Ann Arbor, MI, with a focus on developing innovative solutions in the field of pharmaceuticals. With a total of four patents to his name, his work primarily revolves around inhibiting Mcl-1, a significant player in cancer treatment.
Latest Patents
Guozhi Tang's latest contributions to the field include two notable patents. The first is for "Macrocyclic Indoles as Mcl-1 Inhibitors," which discloses a compound of formula I, including its pharmaceutically acceptable salts and solvates, aimed at treating disorders responsive to Mcl-1 inhibition, specifically cancer. The second patent, "Macrocyclic Spiroethers as Mcl-1 Inhibitors," provides compounds represented by Formula (I-A) that also target cancer treatment through Mcl-1 inhibition, including detailed structural formulas and specifications.
Career Highlights
Throughout his career, Guozhi Tang has made significant strides in research and development. He has worked with esteemed institutions such as the University of Michigan, where he contributed to groundbreaking research, and Ascentage Pharma (Suzhou) Co., Ltd., a company recognized for its commitment to innovative cancer therapies. His expertise in pharmaceutical sciences and dedication to advancing medical treatments has positioned him as a leading figure in his field.
Collaborations
Guozhi has had the opportunity to collaborate with notable coworkers, including Shaomeng Wang and Chao Li. These collaborations have further bolstered his research efforts, allowing for a synergistic approach in developing effective cancer treatments. Such teamwork exemplifies the importance of collaboration in innovation and scientific advancement.
Conclusion
Guozhi Tang's innovative approach to Mcl-1 inhibitors underscores his dedication to transforming cancer treatment. His patents reflect significant contributions to the pharmaceutical industry, showcasing his advancement in medical science. As he continues to push the boundaries of research, his work remains a beacon of hope for those affected by cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile